Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

IMPORTANCE: Clinical outcomes for glioblastoma remain poor. Treatment with immune checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from a randomized phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor therapy for glioblastoma have not been repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Reardon, David A., Brandes, Alba A., Omuro, Antonio, Mulholland, Paul, Lim, Michael, Wick, Antje, Baehring, Joachim, Ahluwalia, Manmeet S., Roth, Patrick, Bähr, Oliver, Phuphanich, Surasak, Sepulveda, Juan Manuel, De Souza, Paul, Sahebjam, Solmaz, Carleton, Michael, Tatsuoka, Kay, Taitt, Corina, Zwirtes, Ricardo, Sampson, John, Weller, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243167/
https://www.ncbi.nlm.nih.gov/pubmed/32437507
http://dx.doi.org/10.1001/jamaoncol.2020.1024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243167/
https://www.ncbi.nlm.nih.gov/pubmed/32437507
http://dx.doi.org/10.1001/jamaoncol.2020.1024

Ejemplares similares